The role of myosins in the pathogenesis of hearing loss is well established: five genes encoding unconventional myosins and two genes encoding nonmuscle conventional myosins have so far been described to be essential for normal auditory function and mutations in these genes associated with hearing impairment. To better understand the role of this gene family we performed a mutational screening on two candidate genes, MYO1C and MYO1F, analyzing hundreds of patients, affected by bilateral sensorineural hearing loss and coming from different European countries. This research activity led to the identification of 6 heterozygous missense mutations in MYO1C and additional 5 heterozygous missense mutations in MYO1F. Homology modelling suggests that some of these mutations could have a potential influence on the structure of the ATP binding site and could probably affect the ATPase activity or the actin binding process of both myosins. This study suggests a role of the above mentioned myosin genes in the pathogenesis of hearing loss.
Introduction
Myosins are actin-based molecular motors, ubiquitously expressed as multiple isoforms in all eukaryotic cells. Almost all myosins known to date are composed of one or two conserved heavy chains, formed by the N-terminal globular motor domain, with ATP-and actinbinding sites, of a "neck" with one or more IQ motifs (that binds calmodulin or calmodulin-like chains) and of at least one variable light chain responsible for the specific function of the myosin [1] [2] [3] . Myosins are commonly classified into conventional myosins, which are similar in the head sequence and structure to muscle myosin, and unconventional myosins whose sequence is similar in the head but different in the tail. During the past years, considerable attention has been paid to the role of unconventional myosins in inner ear sensory hair cells. As a matter of fact, several myosins have been shown to play a relevant role in sound detection and signal transmission processes occurring in sensory hair cells of the cochlea [4, 5] . Five genes encoding unconventional myosins (Ia, IIIa, VI, VIIa and XVa), and two genes encoding nonmuscle conventional myosins (MYH9 and MYH14) are essential for normal auditory function and mutations in these genes have been associated with hearing impairment [6] [7] [8] [9] [10] . Myosin VIIA has been shown to be responsible for Usher syndrome type IB [11] and of a dominant form of nonsyndromic deafness DFNA11 [12, 13] , while its role in causing recessive forms of nonsyndromic deafness (DFNB2) is still controversial [14] [15] [16] . Mutations in MYO6 have been described in human and mice, with a recessive inheritance in the Snell's waltzer mouse [17] , and both autosomal dominant and recessive patterns in humans (DFNA22 and DFNB37) [18, 19] . MYO15A is mutated in human DFNB3 and in mouse shaker-2 [20, 21] . Recently, mutations in MYO3A and in MYO1A have been shown to cause non syndromic forms of recessive hearing loss, DFNB30 and DFNB48, respectively [8, 9] .
Recent data suggest that MYO1C and MYO1F, encoding unconventional myosins expressed in the inner ear, may represent good candidates for hereditary hearing loss in mammals. To evaluate MYO1C and MYO1F as candidate genes for deafness, we analyzed 450 subjects by mutational screening using denaturing high-performance liquid chromatography (DHPLC) and direct sequencing of electrophoretically abnormal fragments.
Materials and methods

Sample
Samples included 450 subjects showing bilateral sensorineuronal hearing loss, without any feature, clinical sign and/or symptoms of known syndromes (visual defects, facial appearance, skin 
Genetic analysis
A set of 20 and 22 primer pairs were designed to amplify MYO1C and MYO1F, respectively (Tables 1 and 2 ). PCR fragments include the coding regions and the splice sites. All amplicons were screened by DHPLC, performed on a WAVE Nucleic Acid Fragment Analysis System HSM (Transgenomic), according to supplier protocols. DHPLC data analysis was based on a subjective comparison of sample and reference chromatograms. PCR products that showed an abnormal chromatographic profile on DHPLC analysis were sequenced directly on an automated sequencer (ABI 3130; Applied Biosystem, USA) using the ABI-PRISM big-dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystem, USA). The possible pathogenicity of variants was also assessed, evaluating the conservation of residues by multiple sequence alignments of homologous proteins obtained with the WU-BLAST algorithm. The presence of mutated alleles was tested on 200 normal chromosomes of individuals coming from the same geographical area of patients (100 healthy controls coming from Belgium, 100 from Italy and 100 from Spain).
Homology modelling
In order to understand the effects of the mutations on protein level, the structures of myosin-1c and myosin-1f proteins were built by homology modelling. In particular, the structures of myosin-1c (a.a. 12-852) and myosin-1f (a.a. 9-733) have been modelled with the program MODELLER (release 8v2) [22] using the crystallographic structure of myosin-2 heavy chain (nonmuscle) from Dictyostelium d. (PDB entry 1g8x, chain A) as a template. In the modelled region, myosin-1c and myosin-1f share respectively 36% and 39% amino acid identity with the sequence of the template myosin (sequence alignments available on request). The ADP molecule co-crystallized with the template myosin structure 1g8x has been retained in its corresponding position also in the myosin-1c and myosin-1f models to indicate the putative binding site of the ATP nucleotide phosphate cofactor. This computational method has allowed prediction of the effects of the mutations falling inside the modelled regions of myosin1c and myosin-1f.
Results and discussion
Variations detected in MYO1C and MYO1F are summarized in Table  3 and Table 4 , respectively.
Myosin-1c
Six missense mutations, at heterozygous state, have been detected in MYO1C gene. 5 of the affected residues are well conserved across species. Variations R156W, V252A and T380M are located in the myosin head domain, while Q750K is located in the third IQ domain; K823N, E831K are located between the third IQ domain and the TH1 domain.
R156W is due to a CNT nucleotide change at position 467. It was detected in a Spanish sporadic case (coming from Mallorca Isle) affected by bilateral sensorineural hearing loss. In this mutation, an arginine, a residue evolutionarily conserved and probably important in ATP binding, is substituted with a tryptophan. Homology modelling predicts that the R156W mutation would cause a strong change in the physical-chemical properties of an amino acid that makes direct contact with the ATP co-factor (Fig. 1A) .
In an Italian patient with a moderate form of bilateral sensorineural hearing loss, the mutational screening highlighted the substitution 756GNA leading to the amino acid change V252A. The evolutionary conserved Val 252 interacts with a group of amino acids that includes Val 145, Ala 148 and Gln 207, contributing to stabilize the arrangement of α-helices nearby the binding site of ATP (Fig. 1B) . Mutations involving Val 252 are therefore expected to interfere with the binding of ATP.
Mutation T380M is due to a GNA nucleotide change at position 1136; it was detected in Spanish subject with a family record of progressive bilateral sensorineural hearing loss and an autosomal dominant pattern of inheritance; the age of onset was 18. The T380M mutation implies the replacement of a polar with a non-polar amino acid in a protein site characterized by tight packing of secondary structure elements. The effects of this mutation are important since T380 interacts with amino acids that contribute to form α-helix directly involved in the binding of ATP (Fig. 1C) . R156W, V252A and T380M mutations occur in the myosin head-like domain, and particularly in sites of the protein that are relevant in ATP binding and/or in the conversion of the chemical energy of this co-factor into mechanical energy, which is fundamental in the myosin-actin interaction.
The Q750K mutation is due to a nucleotide change CNA at position 2248, with a glutamine/lysine substitution and was detected in a Spanish patient affected by bilateral sensorineural hearing loss. K823N, with nucleotide change 2469ANC, was observed in two members of a family: a 10 years old girl with a bilateral mild hearing loss and a 7 years boy affected by moderate/severe bilateral sensorineural hearing loss. The age of onset was approximately 3 years old. Biological samples of their parents were not available.
Finally
In conclusion, 5 of the six alleles identified in MYO1C affect residues highly conserved across species and for 3 of them bioinformatic analysis strongly suggest a relevant functional role.
Myosin-1f
For MYO1F, six missense variations have been detected, each one at heterozygous state. Five of these amino acid changes involve evolutionary highly conserved residues. The missense mutation P84L was detected in a patient coming from Belgium; it is due to a CNT nucleotide change at position 251, near the ATP-binding site (relative to ATG, designated +1), with a proline/glutamic acid substitution. Pro 84 makes direct contact with groups of surrounding residues (Asp 20 carboxylic group, Phe 47 amide carbonyl group, and Tyr 49 hydroxyl group). In addition, Pro 84 is also solvent-exposed, which is a common feature for proline residues. The P84L mutation implies replacement of Pro 84 with a leucine, a residue characterized by a high tendency to locate away from the solvent. This mutation is likely to cause a local structural destabilization and influencing the nearby binding site of ATP (Fig. 1D) .
Mutation c.649ANT was detected in an Italian patient with a moderate form of sensorineural hearing loss. This nucleotide variation is located in exon 9 and causes the substitution of the alanine at position 217 with a threonine (A217T). Ala 217 is partially conserved in the evolutionary scale and is involved in hydrophobic interactions with the side chains of Leu 213 (one of the two δ- carbon atoms), Gln 221 (the β-carbon atom) and Leu 227 (one of the two δ-carbon atoms). The A217T amino acid change introduces a threonine containing a polar side chain that cannot properly replicate the hydrophobic interactions of the smaller and apolar alanine residue. This mutation is expected to introduce an alteration in a region of the protein that is also characterized by tight interactions between secondary structure elements that are close to the ATP binding site (Fig. 1E ). I502V and K552N are two missense mutations detected in patients coming from Belgium and affected by mild to moderate bilateral sensorineuronal hearing loss; these variations are due to an ANG and CNG change, at positions 1504 and 1656, implying an isoleucine/valine and a lysine/asparagine substitution respectively. These amino acids are located near the actin-binding sites of myosin-1f. Ile 502 is part of β-sheet in the head of myosin-1f and contributes to stabilize the protein structure through its hydrophobic interactions with Val 444, Leu 447 and Ile 448 residues located on a neighbouring α-helix (Fig. 1F) . The I502V mutation may disrupt this set of interactions interfering with the binding of ATP. The P84L, A217T and I502V mutations occur close to the ATP binding site in the myosin head-like domain and might interfere with the correct binding of the co-factor. D776N is a missense mutation due to a GNA nucleotide change at position 2296, in the TH1 domain and leads to a substitution of an Fig. 1 . Homology modelling of the sites of mutation falling within the head domain of myosin-1c and myosin-1f obtained using the crystallographic structure of myosin-2 heavy chain (nonmuscle) from Dictyostelium d. (PDB entry 1g8x, chain A) as a template. Represented are the protein backbone (green ribbon-like structure), the amino acid site of mutation (sticks with red surface), sets of selected amino acids (sticks with cyan surface) showing critical interactions with the mutated residues, and the ADP ligand (stick representation) used to evidence the putative site of binding of the nucleotide phosphate co-factor. Details of myosin-1c structure in proximity of the mutating residues R156, V252 and T380 are shown in panels A, B and C, respectively. Details of myosin-1f regions containing the mutated residues P84, A217 and I502 are shown in panels D, E and F, respectively. aspartic acid with an asparagine. Aspartic acid is a residue highly conserved and probably functionally important. It was detected in a Spanish patient affected by bilateral sensorineural hearing loss. It segregates within the family since it was inherited from the affected father and also transmitted by the proband to the affected daughter but not to the healthy one (dominant patter of inheritance). It was also detected in a normal hearing member of the family; this information could exclude its pathogenic role, even if we cannot discard the hypothesis that this subject can manifest a hearing impairment in the future.
Finally, R1027Q was detected in a Spanish patient affected by early onset progressive sensorineuronal hearing loss. This variation is due to a GNA nucleotide change at position 3080; arginine 1027 is located between the TH1 and SH3 domains. For this variation a pathogenic role was excluded since it wasn't detected in the other affected members of the probands family.
Thus, summarizing, 5 alleles affect residues conserved across species, and prediction by homology modelling suggest a role for 3 of them.
Conclusions
The pathogenic role of more than 40 genes has already been described for hearing impairment. Within this heterogeneous group of genes, 7 belong to myosin superfamily and explain both syndromic and nonsyndromic forms. Expression, functional data and involvement in hearing physiology suggest that other members of the myosin superfamily could contribute to hearing loss. Since both MYO1C and MYO1F are known to be expressed in cochlea and since MYO1F is located in DFNB15, they can be considered good candidate genes for nonsyndromic hearing loss.
Here we report the identification of 11 heterozygous missense mutations in MYO1F and MYO1C, both clearly expressed in inner ear, in patients affected by bilateral sensorineuronal hearing loss.
MYO1C is a member of the family of unconventional type 1 myosins, characterized by the presence of the head domain (or motor domain), three or four IQ domains and the TH1 domain (or tail domain) at the C-terminus; the tail domain is rich in basic residues which allow interactions with negatively charged membrane phospholipids. Myosin-1c plays an essential role in adaptation of hair-cell mechano-electrical transduction [23] . Recent experiments confirmed that myosin-1c is a component of the hair cell's adaptation-motor complex, directly or indirectly interacting with other components of the transduction apparatus to mediate slow adaptation [24] .
Furthermore, myosin-1c has been proposed as a motor protein that sets a resting tension on the tip link and the channels during fast adaptation processes [25] [26] [27] . Moreover, recent data indicate that myosin-1c interacts in vitro with three other molecules proposed to be important for transduction: cadherin 23 (CDH23), phosphatidylinositol 4,5-bisphosphate (PIP2) [28] and PHR1, an integral membrane protein [29] .
The six missense mutations here reported suggest a pathogenic role of myosin-1c gene in hearing loss. The homology modelling proposes that mutations located in the head of myosin-1c have a strong influence on its functionality: they are predicted to affect sites of the protein relevant in ATP binding and/or in the conversion of the chemical energy of this co-factor into mechanical energy. Instead, the other missense mutations are located in IQ3, a domain, as suggested by Phillips et al. [28] , involved in the regulation of myosin-1c activity by Ca 2+ and in calmodulin binding, or in the region of interaction with PHR1. As hypothesized by Etournay et al. [29] PHR1 and myosin-1c form a complex acting as elastic molecular cross linker that contribute to and modulate the membrane tension in the slow adaptation process: the increasing of the stereociliar Ca 2+ concentration through the open MET channels leads to the dissociation of myosin molecules from actin filaments, decreasing the MET channel open probability.
Summarizing, for MYO1C, all the mutated alleles described in this study can modify the adaptation process in which myosin-1c and PHR1 have an important role: a) mutations in the head of the protein could modify the conversion of the chemical energy of this co-factor into mechanical energy or the actin binding process; b) mutation in IQ motifs could change the regulatory function of Ca 2+ [30] . The amino acid sequence suggests the presence of a head domain, a single IQ domain, the TH1 domain and at the C-terminus an SH3 domain as mediator of protein-protein interactions [31] . Kim et al. [32] demonstrated that in mice, Myo1f is expressed predominantly in the mammalian immune system, and it was hypothesized that this protein could direct immune cell motility and innate host defence against infection. MYO1F was selectively expressed in neutrophils and was shown to be indispensable for both phagocytosis of bacteria and their destruction: it inhibits exocytosis of integrin containing granules in neutrophils, preventing excess of adhesion. Myosin-1f deficient neutrophils show a stronger adhesion to integrin ligands [33] . Since the inner ear immune response seems to be basically cellular [34] , a possible affection of integrin mediated adhesion related to myosin-1f defects could increase the susceptibility to infections or could cause a neutrophil impaired response, leading to auditory tissues damage due to reactive oxygen species. Homology modelling showed that all mutations detected in the MYO1F head can seriously affect ATP binding, probably by reducing or modifying myosin-1f function. On the basis of the role of myosin-1f in the mammalian immune system, we can assume that hearing loss in these patients can be due to an increased susceptibility to infections or to an abnormal neutrophilic response with the production of reactive oxygen species (ROS) and the subsequent involvement of proteolysis enzymes and antimicrobial proteins [32] .
For both myosin-1c and myosin-1f, mutations detected in the head domain could have a potential influence on the structure of the ATP binding site and could probably affect their ATPase activity, although it cannot be excluded that mutations in the head domain might also interfere with the actin binding process. Moreover, structural studies on myosins suggest that the interaction with actin requires large conformational changes that involve several residues, and no clear identification of all the amino acids composing the actin-binding regions is available yet. For MYO1C mutations located in other portions of the protein, we can hypothesize a modification of the regulatory function of Ca 2+ or calmodulin on the myosin-1c activity or that of PHR1 interaction.
In conclusion, a) both genes are expressed in the inner ear and thus have been selected as good candidates; b) mutants have been detected at the heterozygous state in hearing impaired people but not in normal controls; c) the vast majority of the alleles here described affect residue highly conserved across species; d) modelling homology, whenever applied, strongly suggest a functional role of mutants; e) whenever possible a segregation within families was shown. We cannot rule out the possible presence of rare recessive alleles or the identification of carriers in which the cause of hearing loss is attributable to other genes, but all our findings suggest to exclude a mutational load and propose a possible causative role of the above mentioned genes in hearing loss. Future studies will better define the role of MYO1C and MYO1F mutants in causing hearing loss.
